Boehringer Ingelheim To Boost Cancer Immunology Portfolio with Novel Cancer Vaccines

 
• By Sten Stovall
Vial
AMAL’s KISIMA platform leverages peptide/protein-based vaccination technology • Source: Shutterstock

More from Deals

More from Business